Lancet Oncology最新文献

{"title":"The pathway for surgery as an integral part of attaining universal health coverage.","authors":"Bente Mikkelsen, Raffaella Casolino","doi":"10.1016/S1470-2045(23)00566-1","DOIUrl":"10.1016/S1470-2045(23)00566-1","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"1298-1301"},"PeriodicalIF":41.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV vaccine roll-out in Nigeria and Bangladesh.","authors":"Munyaradzi Makoni","doi":"10.1016/S1470-2045(23)00571-5","DOIUrl":"10.1016/S1470-2045(23)00571-5","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"1311-1312"},"PeriodicalIF":41.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide.","authors":"Chandrakanth Are, Shilpa S Murthy, Richard Sullivan, Makayla Schissel, Sanjib Chowdhury, Olesegun Alatise, Daniel Anaya, Madhuri Are, Charles Balch, David Bartlett, Murray Brennan, Lydia Cairncross, Matthew Clark, S V S Deo, Vikas Dudeja, Domenico D'Ugo, Ibtihal Fadhil, Armando Giuliano, Satish Gopal, Lily Gutnik, Andre Ilbawi, Pankaj Jani, T Peter Kingham, Laura Lorenzon, Premila Leiphrakpam, Augusto Leon, Hector Martinez-Said, Kelly McMasters, David O Meltzer, Miriam Mutebi, Syed Nabeel Zafar, Vibhavari Naik, Lisa Newman, Alexandre Ferreira Oliveira, Do Joong Park, C S Pramesh, Saieesh Rao, T Subramanyeshwar Rao, Enrique Bargallo-Rocha, Anya Romanoff, Anne F Rositch, Isabel T Rubio, Heber Salvador de Castro Ribeiro, Eman Sbaity, Maheswari Senthil, Lynette Smith, Masakazi Toi, Kiran Turaga, Ujwal Yanala, Cheng-Har Yip, Ashraf Zaghloul, Benjamin O Anderson","doi":"10.1016/S1470-2045(23)00412-6","DOIUrl":"10.1016/S1470-2045(23)00412-6","url":null,"abstract":"<p><p>The first Lancet Oncology Commission on Global Cancer Surgery was published in 2015 and serves as a landmark paper in the field of cancer surgery. The Commission highlighted the burden of cancer and the importance of cancer surgery, while documenting the many inadequacies in the ability to deliver safe, timely, and affordable cancer surgical care. This Commission builds on the first Commission by focusing on solutions and actions to improve access to cancer surgery globally, developed by drawing upon the expertise from cancer surgery leaders across the world. We present solution frameworks in nine domains that can improve access to cancer surgery. These nine domains were refined to identify solutions specific to the six WHO regions. On the basis of these solutions, we developed eight actions to propel essential improvements in the global capacity for cancer surgery. Our initiatives are broad in scope, pragmatic, affordable, and contextually applicable, and aimed at cancer surgeons as well as leaders, administrators, elected officials, and health policy advocates. We envision that the solutions and actions contained within the Commission will address inequities and promote safe, timely, and affordable cancer surgery for every patient, regardless of their socioeconomic status or geographic location.</p>","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"e472-e518"},"PeriodicalIF":41.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IASLC calls for clinical trials to use tobacco use data.","authors":"Bryant Furlow","doi":"10.1016/S1470-2045(23)00569-7","DOIUrl":"10.1016/S1470-2045(23)00569-7","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"1309"},"PeriodicalIF":41.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An HPV vaccine from India: broadening possibilities for cervical cancer control.","authors":"John T Schiller, Aimée R Kreimer","doi":"10.1016/S1470-2045(23)00535-1","DOIUrl":"10.1016/S1470-2045(23)00535-1","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"1288-1289"},"PeriodicalIF":41.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72209828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.","authors":"Reinhard Dummer, Paola Queirolo, Pauline Gerard Duhard, Youyou Hu, Dao Wang, Sergio Jobim de Azevedo, Caroline Robert, Paolo Antonio Ascierto, Vanna Chiarion-Sileni, Paolo Pronzato, Francesco Spagnolo, Karmele Mujika Eizmendi, Gabriella Liszkay, Luis de la Cruz Merino, Hussein Tawbi","doi":"10.1016/S1470-2045(23)00334-0","DOIUrl":"10.1016/S1470-2045(23)00334-0","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Targeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases. We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;TRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAF&lt;sup&gt;V600&lt;/sup&gt; wild-type cohort and a BRAF&lt;sup&gt;V600&lt;/sup&gt; mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland. Eligible patients were aged 18 years or older with previously untreated metastatic melanoma, brain metastases of 5 mm or larger in at least one dimension, and an Eastern Cooperative Oncology Group performance status of 2 or less. Patients in the BRAF&lt;sup&gt;V600&lt;/sup&gt; wild-type cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral cobimetinib (60 mg once daily, days 1-21). Patients in the BRAF&lt;sup&gt;V600&lt;/sup&gt; mutation-positive cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral vemurafenib (720 mg twice daily) plus oral cobimetinib (60 mg once daily, days 1-21); atezolizumab was withheld in cycle 1. Treatment was continued until progression, toxicity, or death. The primary outcome was intracranial objective response rate confirmed by assessments at least 4 weeks apart, as assessed by independent review committee (IRC) using modified Response Evaluation Criteria in Solid Tumours version 1.1. Because of early closure of the BRAF&lt;sup&gt;V600&lt;/sup&gt; wild-type cohort, the primary endpoint of intracranial objective response rate by IRC assessment was not done in this cohort; intracranial objective response rate by investigator assessment was reported instead. Efficacy and safety were analysed in all patients who received at least one dose of study medication. This trial is closed to enrolment and is registered with ClinicalTrials.gov, NCT03625141.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Between Dec 13, 2018, and Dec 7, 2020, 65 patients were enrolled in the BRAF&lt;sup&gt;V600&lt;/sup&gt; mutation-positive cohort; the BRAF&lt;sup&gt;V600&lt;/sup&gt; wild-type cohort was closed early after enrolment of 15 patients. Median follow-up was 9·7 months (IQR 6·3-15·0) for the BRAF&lt;sup&gt;V600&lt;/sup&gt; mutation-positive cohort and 6·2 months (3·5-23·0) for the BRAF&lt;sup&gt;V600&lt;/sup&gt; wild-type cohort. Intracranial objective response rate was 42% (95% CI 29-54) by IRC assessment in the BRAF&lt;sup&gt;V600&lt;/sup&gt; mutation-positive cohort and 27% (95% CI 8-55) by investigator assessment in the BRAF&lt;sup&gt;V600&lt;/sup&gt; wild-type cohort. Treatment-related grade 3 or worse adverse events occurred in 41 (68%) of 60 patients who received atezolizumab plus vemurafenib plus cobimetinib in the BRAF&lt;sup&gt;V600&lt;/sup&gt; mutation-positive cohort, the most common of which we","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"e461-e471"},"PeriodicalIF":51.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10419741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.","authors":"Galina Velikova, James P Morden, Joanne S Haviland, Charlotte Emery, Peter Barrett-Lee, Helena Earl, David Bloomfield, Adrian Murray Brunt, Peter Canney, Robert Coleman, Mark Verrill, Andrew Wardley, Gianfilippo Bertelli, Paul Ellis, Rob Stein, Judith M Bliss, David Cameron","doi":"10.1016/S1470-2045(23)00460-6","DOIUrl":"10.1016/S1470-2045(23)00460-6","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Adjuvant chemotherapy for patients with early breast cancer improves outcomes but its toxicity affects patients' quality of life (QOL). The UK TACT2 trial investigated whether accelerated epirubicin improves time to recurrence and if oral capecitabine is non-inferior to cyclophosphamide, methotrexate, and fluorouracil (CMF) for efficacy with less toxicity. Results showed no benefit for accelerated epirubicin and capecitabine was non-inferior. As part of the QOL substudy, we aimed to assess the effect of chemotherapies on psychological distress, physical symptoms, and functional domains.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;TACT2 was a multicentre, phase 3, open-label, parallel-group, randomised, controlled trial done in 129 UK centres. Participants were aged 18 years or older with histologically confirmed node-positive or high-risk node-negative invasive primary breast cancer, who had undergone complete excision, and due to receive adjuvant chemotherapy. Patients were randomly assigned (1:1:1:1) to four cycles of 100 mg/m&lt;sup&gt;2&lt;/sup&gt; epirubicin either every 3 weeks (standard epirubicin) or every 2 weeks with 6 mg pegfilgrastim on day 2 of each cycle (accelerated epirubicin), followed by four 4-week cycles of either CMF (600 mg/m&lt;sup&gt;2&lt;/sup&gt; cyclophosphamide intravenously on days 1 and 8 or 100 mg/m&lt;sup&gt;2&lt;/sup&gt; orally on days 1-14; 40 mg/m&lt;sup&gt;2&lt;/sup&gt; methotrexate intravenously on days 1 and 8; and 600 mg/m&lt;sup&gt;2&lt;/sup&gt; fluorouracil intravenously on days 1 and 8 of each cycle) or four 3-week cycles of 2500 mg/m&lt;sup&gt;2&lt;/sup&gt; capecitabine (1250 mg/m&lt;sup&gt;2&lt;/sup&gt; given twice daily on days 1-14 of each cycle). The randomisation schedule was computer generated in random permuted blocks, stratified by centre, number of nodes involved (none vs 1-3 vs ≥4), age (≤50 years vs &gt;50 years), and planned endocrine treatment (yes vs no). QOL was one of the secondary outcomes and is reported here. All patients from a subset of 44 centres were invited to complete QOL questionnaires (Hospital Anxiety and Depression Scale [HADS] and European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire 30-item core module [QLQ-C30] and Quality of Life Questionnaire breast module [QLQ-BR23]) at baseline, end of standard or accelerated epirubicin, end of CMF or capecitabine, and at 12 and 24 months after randomisation. The QOL substudy prespecified two coprimary QOL outcomes assessed in the intention-to-treat population: overall QOL (reported elsewhere) and HADS total score. Prespecified secondary QOL outcomes were EORTC QLQ-C30 subscales of physical function, role function, and fatigue and EORTC QLQ-BR23 subscales of sexual function and systemic therapy side-effects. This trial is registered with ISRCTN, ISRCTN68068041, and ClinicalTrials.gov, NCT00301925.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;From Dec 16, 2005, to Dec 5, 2008, 4391 patients (20 [0·5%] of whom were male) were enrolled in TACT2; 1281 (85·8%) of 1493 eligible","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"1359-1374"},"PeriodicalIF":41.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proposal to lower Australia's bowel screening age limit from 50 to 45 years.","authors":"Tony Kirby","doi":"10.1016/S1470-2045(23)00570-3","DOIUrl":"10.1016/S1470-2045(23)00570-3","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"1310"},"PeriodicalIF":41.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer surgery: orchestrating cancer control by strengthening health systems.","authors":"Mary Gospodarowicz, Anna Dare, David A Jaffray","doi":"10.1016/S1470-2045(23)00484-9","DOIUrl":"10.1016/S1470-2045(23)00484-9","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"1297-1298"},"PeriodicalIF":41.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global cancer surgery: a vital service to eliminate false economy.","authors":"Allison Landman, David Collingridge","doi":"10.1016/S1470-2045(23)00533-8","DOIUrl":"10.1016/S1470-2045(23)00533-8","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"1296-1297"},"PeriodicalIF":41.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}